If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
99
results.
Updated on
12/01/2026 [06:56:00]
Absstract of: WO2026008357A1
In an approach to determining stress contributions to blood glucose levels, the present invention receives a blood glucose signal over a first period of time and a biomarker signal over a second period of time. The present invention extracts one or more blood glucose level signal features from the blood glucose signal, one or more biomarker signal features from the biomarker signal to determine a blood glucose level of time-based stress contribution and a biomarker-based stress contribution.
Absstract of: WO2026008380A1
In an approach to interpreting changes in blood glucose levels, the present invention receives a blood glucose signal from one or more sensors over a period of time. The present invention further contemplates the extraction of one or more features of the blood glucose signal received from the one or more sensors. Using this information, a relative non-digestion- related contribution to the blood glucose signal is determined based on one or more features extracted from the blood glucose signal. It is further contemplated that a relative digestion- related contribution to the blood glucose signal is determined based on the one or more features extracted from the blood glucose signal. In some cases, an absolute digestion related contribution and/or an absolute non-digestion-related contribution is determined from the relative digestion-related and non-digestion-related contributions.
Absstract of: WO2026009101A1
A method for continuous glucose monitoring includes a processor of a computing device operatively coupled to or integrated with a display receiving data. The data includes a plurality of glucose levels, and each glucose level of the plurality of glucose levels is associated with a corresponding time. The processor processes the data to generate a first graphical element indicative of a current glucose level, and one or more second graphical elements indicative of a rate and a direction of change of the glucose level. The processor via a graphical user interface displays the first graphical element on the display and the one or more second graphical elements on the display. The one or more second graphical elements are positioned relative to the first graphical element to visually indicate whether the glucose level is stable, increasing, or decreasing.
Absstract of: WO2026008436A1
In an approach to interpreting changes in blood glucose levels, the present invention receives a blood glucose signal from one or more sensors over a period of time and a biomarker signal from one or more sensors over an overlapping period of time. The present invention further contemplates the extraction of one or more features of the biomarker signal received from the one or more sensors. Using this information, a relative non-digestion-related contribution to the blood glucose signal is determined based on one or more features extracted from the blood glucose signal. It is further contemplated that a relative digestion-related contribution to the blood glucose signal is determined based on the one or more features extracted from the blood glucose signal. In some cases, an absolute digestion related contribution and/or an absolute non-digestion-related contribution is determined from the relative digestion-related and non-digestion-related contributions.
Absstract of: WO2026008858A1
A blood glucose level sensing device for non-invasive blood glucose level measurement of a subject is disclosed. The device comprises: a digit-depth unit configured to measure or receive a depth of a digit of the subject; a measurement light generation element configured to direct measurement light through the digit; and a light-transmission measurement unit configured to measure a transmission index representing the proportion of the measurement light transmitted through the digit. The device also has a digit characteristic parameter unit configured to receive one or more digit characteristic parameters indicative of: a skin tone of the digit; a nail texture of the digit; a nail thickness of the digit; a nail length of the digit; and a nail polish status of the digit. The device is configured to determine a blood glucose level measurement based on the transmission index, the depth of the digit and at least one of the digit characteristic parameters. Also disclosed is a method of non-invasively determining a blood glucose level of a subject via a digit of the subject.
Absstract of: WO2026008382A1
In an approach to estimating diabetes risk, the present invention receives a biomarker signal over a first period of time. From the biomarker signal, the presently claimed invention extracts one or more features of the biomarker signal and determines a first trend associated with insulin resistance based on the one or more features of the biomarker signal. Using this information, the present invention can determine a relative non-digestion-related contribution to the blood glucose signal and/or a relative digestion-related contribution to the blood glucose signal is determined based on the one or more features extracted from the blood glucose signal. In some cases, an absolute digestion related contribution and/or an absolute non-digestion- related contribution is determined from the relative digestion-related and non-digestion-related contribution.
Absstract of: AU2025271165A1
Abstract Described herein are variations of an analyte monitoring system, including an analyte monitoring device. For example, an analyte monitoring device may include an implantable microneedle array for use in measuring one or more analytes (e.g., glucose), such as in a continuous manner. The microneedle array may include, for example, at least one microneedle including a tapered distal portion having an insulated distal apex, and an electrode on a surface of the tapered distal portion located proximal to the insulated distal apex. At least some of the microneedles may be electrically isolated such that one or more electrodes is individually addressable. WO 2022/026764 PCT/US2021/043786 160 110 FIG. 1 Additional 128Sensor(s) Sensor Microneedle\ Controller(s) Comm. Array Circuitry Module(s) 140 124 126 a Power Circuitry Source(s) ov o v e n s o r i c r o n e e d l e \ o m m o w e r
Absstract of: WO2026010518A1
The aim of the invention is to provide for virtually continuous monitoring of a person's blood glucose level in the case of the occurrence and repair of a fault in a wrist-worn blood glucose monitoring device caused by the breakage of wires or failure of a sensor which are located in a section of a strap or wristband by permitting expeditious replacement of the section containing the sensor and wires. The technical results of the invention include: permitting expeditious repair of a wire breakage or sensor failure-related fault in the device by replacement of a section of the strap or wristband, wherein the time required to replace the section of the strap or wristband is not greater than the interval between blood glucose level measurements; permitting the use of the body of the device with strap or wristband sections of different lengths; and permitting expeditious replacement of sections of the strap or wristband of the device if the wearer has an allergic reaction to the material of the sections of the strap or wristband.
Absstract of: EP4675641A1
The invention discloses an automatic detection method based on the change rate of the difference between the actual blood glucose values, including: obtaining an actual blood glucose value of the user at the current time; obtaining a historical actual blood glucose value of the user at the previous time, and calculate a difference between the actual blood glucose values at the current time and at the previous time; calculating a change rate of the difference between the actual blood glucose values at the current time; and comparing the change rate of the difference between the actual blood glucose values at the current time with a preset threshold, and determining an event type according to the comparing result. According to the determined event type, the artificial pancreas can automatically adjust the corresponding infusion strategy to achieve closed-loop control of the artificial pancreas.
Absstract of: US2024315611A1
Blood glucose states based at least on sensed brain activity data. Blood glucose states may be predicted states using prediction models, and may be real-time or future glucose states. One or more wearable sensors, optionally adapted for use in either single channel or dual channel sensing, can record brain activity signals and communicate brain activity signal data to a remote device.
Absstract of: WO2026000747A1
The present invention relates to the field of disease prediction, and in particular, to a gastrointestinal electrical signal-based diabetes and hypertension prediction system and a construction method. The prediction system provided by the present invention comprises: a database, used for storing gastrointestinal electrical signal data, comprising the postprandial coupling percentage at the lesser curvature lead, the postprandial electrical dysrhythmia percentage at the gastric antrum lead, the preprandial dominant frequency at the lesser curvature lead, the postprandial average waveform frequency at the ascending colon lead, the postprandial normal slow wave percentage at the ascending colon lead, the postprandial coupling percentage at the descending colon lead, the postprandial average waveform frequency at the rectal lead, the preprandial average waveform frequency at the transverse colon lead, and the preprandial lead time difference at the rectal lead; and a prediction module, used for predicting a probability of the occurrence of diabetes and hypertension in a subject. Further provided in the present invention is a construction method for the prediction system. The present invention is adapted to performing diabetes and hypertension risk prediction and screening work in rural or community populations.
Absstract of: WO2026001285A1
The present application provides a blood glucose and blood oxygen multi-parameter detection chip and a wearable device. The present application relates to the technical field of semiconductors. The multi-parameter detection chip comprises a coupler, a gating device, and a plurality of outlets that are optically connected in sequence and integrated together, as well as a light source capable of emitting light of different wavelengths and a detector. The coupler is configured for coupling the light of different wavelengths emitted by the light source to the gating device. The gating device selects the light of different wavelengths and allows the light to enter the corresponding outlets so that the light exits by means of the outlets. The detector is configured for receiving the light that exits by means of the outlets and is then reflected or transmitted back. Arranging an array of outlets and replacing traditional point detection with plane detection can greatly improve the detection accuracy. In addition, the wavelength coverage of the blood glucose and blood oxygen multi-parameter detection chip spans the entire visible to near-infrared light waveband, so that the chip can perform multi-wavelength detection, thereby enabling multi-parameter measurement.
Absstract of: WO2026002585A1
The invention concerns a method for determining a substance concentration in a sample comprising liquid containing particles, in particular glucose in blood, wherein a refractive index of the liquid is dependent on a concentration of the substance dissolved therein and a density of particles in the liquid is substantially constant, wherein the liquid is modulated in its volume or pressure. The proposed method obtains a first signal during a first time period with an acquisition rate that is at least two times larger than a periodicity of the volume or pressure modulation of the liquid and determines a variability therefrom. The variability or its change thereof over time directly corresponds to the concentration of the substance or a change thereof.
Absstract of: WO2026005140A1
According to various embodiments, a server for predicting determination on a diabetic foot on the basis of a plurality of pieces of data on the basis of a prediction model, comprises: a communication interface; a memory; and a processor, wherein the processor is configured to: obtain at least one piece of image data and at least one piece of first sensing data from an external server of an external user through the communication interface; obtain first ulcer output data by inputting the at least one piece of image data and the at least one piece of first sensing data to the prediction model; when it is determined that the first ulcer output data exceeds a preset first threshold value on the basis of a result of comparing the first ulcer output data with the preset first threshold value, output that a foot ulcer of the external user is likely to be diabetic foot ulcer; when it is determined that the first ulcer output data exceeds a second threshold value set to be greater than the first threshold value on the basis of a result of comparing the first ulcer output data with the second threshold value, output that the foot ulcer of the external user is highly likely to be the diabetic foot ulcer; and transmit, through the communication interface, result data for the first ulcer output data determined to exceed the first threshold value and/or the second threshold value, and guideline data presenting at least one guideline on the basis of the result data, wherein the prediction m
Absstract of: WO2026005935A1
An encasement material that resists degradation, including yellowing. The encasement material may be used, for example, in an apparatus including a housing, circuitry at least partially within the housing, that is implanted into an animal (e.g. a human) to continuously monitor the concentrations of specific analytes, such as glucose. The encasement material allows for the efficient transmission of excitation and emission light to and from an analyte indicator in the device. The encasement material includes additives that resist and inhibit degradation of the encasement material thereby improving the longevity and life of the device. Also, methods for forming the encasement material and incorporating the encasement material within an apparatus.
Absstract of: WO2026006322A1
Constituents of a liquid, such as blood, may exhibit optical signatures that allow for real-time, dynamic concentration detection. For example, concentrations of substances in aqueous solutions, including calcium, potassium, sodium, bicarbonate, chloride, magnesium, phosphate, lactate, acetate, glucose, creatinine, urea, and/or hydrogen peroxide, may be monitored during dialysis or other treatments. This is achieved by measuring real-time changes in light intensity at wavelengths corresponding to the constituents' optical signatures. Concentration may be determined using a predetermined relationship between light intensity and concentration at isolated wavelengths. Real-time monitoring enables timely treatment adjustments, improving patient outcomes.
Absstract of: EP4671378A1
The invention relates to chemical, electrochemical and non-covalently bioconjugation (functionalization) of proteins with catalytic properties. A functionalization method is disclosed using all organic solvents except dimethylformamide (DMF), and dimethyl sulfoxide (DMSO), and utilizing organic synthesis and non-covalent insertion methods. Furthermore, the invention encompasses the preparation of bioelectrodes designed for the detection of substances, including but not limited to glucose, lactose, galactose (as carbohydrates), dopamine, adrenaline (epinephrine), noradrenaline (norepinephrine), and serotonin (as neurotransmitters), L-glutamate, D- or L-amino acids, hydrogen peroxide, nicotine, cholesterol, ethanol, oxalate, lactate, and pyruvate in food products, as well as in human body fluids serving as real samples. Additionally, this invention extends to the utilization of bioelectrodes for monitoring chemical processes, including features and the chemical environment of neuron interfaces within the brain. The invention encompasses an electrochemical inhibitor testing system utilizing the aforementioned bioelectrodes, and the functionalized proteins as single-molecular protein-based memristors.
Absstract of: WO2024175636A1
The invention relates to a system for regulating the concentration of glucose in the blood of a person, comprising: - a device for selectively supplying at least one and preferably two substances, - at least one and preferably two infusion sets connectable to said device for infusing a said substance to said person; - at least one sensor for measuring a glucose concentration in the blood of said person; - a controller for controlling said device such that a certain amount of a said substance is supplied per time unit and thereby infused into the body of the person via said or a respective infusion set, wherein said certain amount is chosen in accordance with the measured glucose concentration, wherein said controller is arranged to determine a slope of the measured glucose concentration, and wherein the time unit per which the certain amount is supplied is dependent on said slope.
Absstract of: WO2024179895A1
The invention relates to a system for regulating the concentration of glucose in the blood of a person, comprising: - a device for selectively supplying insulin and glucagon, - at least two infusion sets; - at least one sensor for measuring a glucose concentration in the blood of said person, and - a controller for controlling said device such that a certain amount of insulin and glucagon is supplied per time unit, wherein said certain amount is chosen in accordance with the measured glucose concentration as prescribed by an insulin injection curve and a glucagon injection curve, wherein said controller is further arranged to determine if glucagon is supplied to said person in a chosen time frame, and wherein the controller is arranged to re-assess and optionally adjust the insulin injection curve based on the determination if glucagon is supplied to said person in said chosen time frame.
Absstract of: WO2024175639A1
The invention relates to a system for regulating the concentration of glucose in the blood of a person, comprising: - a device for selectively supplying at least one and preferably two substances to said person, - at least one and preferably two infusion sets connectable to said device; - at least one sensor for measuring a glucose concentration in the blood of said person; - a controller for controlling said device such that a certain amount of a said substance is supplied per time unit, wherein said controller is arranged to determine a slope of the measured glucose concentration and if said slope exceeds a first threshold value said controller is arranged to control the device to supply a pre-injection amount of said at least one substance, said pre-injection amount being a percentage of a maximum pre-injection amount, wherein said percentage is dependent on the determined slope.
Absstract of: EP4671882A2
The present disclosure relates to a system for closed loop control of glycemia. In one arrangement, the system comprises: an insulin delivery device; a user interface for inputting patient data, the patient data including a basal insulin profile, an insulin-to-carbohydrate ratio, and meal data; and a controller in communication with the user interface and the insulin delivery device and configured to receive glucose data. The controller is further configured to execute: estimating an amount of active insulin in the patient, the active insulin not including the basal insulin profile, determining a meal carbohydrate value from the meal data, estimating a physiological glucose for the patient and a rate of change of physiological glucose based in part on the glucose data, determining an attenuation factor based on the physiological glucose and the rate of change of the physiological glucose, determining a meal bolus based on meal data, the insulin-to-carbohydrate ratio, and the determined attenuation factor, modifying the determined meal bolus based on the estimated amount of active insulin in the patient, and transmitting a request to deliver the modified meal bolus to the insulin delivery device.
Absstract of: WO2024178261A1
A method, system, and computer readable medium for implementing the Adaptive Bio-Behavioral Control concept, which allows for bi-directional, human-machine co-regulation of metabolic disorders, such as diabetes mellitus. The Adaptive Bio-Behavioral Control concept may encompass, but is not limited thereto, three modules: a) a Physiological Adaptation Module which processes a user's historical data to estimate a personalized model of the user's glucose metabolism and to calculate suggested insulin-dosing parameters; b) a Behavioral Adaptation Module which assists the user's adaptation to the treatment action by determining a plurality of actionable information and risk assessments based on the user's glucose monitoring records; and c) a Replay Module which computes a simulation of effects from hypothetical changes to the user's treatment or behavior based on a personalized model of the user's glucose metabolism.
Absstract of: WO2025261683A1
The present disclosure refers to a computer implemented method for detecting an operation status of an analyte sensor (10) for continuous monitoring an analyte, comprising: receiving continuous monitoring data for an analyte detected by an analyte sensor (10); detecting a loss of sensitivity for the analyte sensor (10), comprising determining a sensitivity indicator indicative of a sensor sensitivity of the analyte sensor (10) from the continuous monitoring data, providing a critical measure for the sensitivity indicator, and determining the loss of sensitivity for the analyte sensor (10), if the sensitivity indicator matches the critical measure for the sensitivity indicator; and detecting a defect status for the analyte sensor (10), comprising receiving an impedance value indicative of an impedance measured for the analyte sensor (10), providing a critical measure for the impedance of the analyte sensor (10), and determining the defect status for the analyte sensor (10), if the impedance value matches the critical measure for the impedance of the analyte sensor (10). A failure of the analyte sensor (10) is detected if for the analyte sensor (10) at least one of the loss of sensitivity and the defect status is determined, and, in response to detecting the failure of the analyte sensor (10), at least one of providing failure data indicative of the failure of the analyte sensor (10) and deactivating the analyte sensor (10) is conducted. Further, a computer system, a computer p
Absstract of: WO2025264901A1
Disclosed herein are formulations of antibodies directed against plasma kallikrein, e.g., anti-plasma kallikrein antibodies. The formulations include, for example, amino acids, sugars, and surfactants. The disclosed formulations are useful for administration to subjects to treat plasma kallikrein associated disorders such as hereditary angioedema (HAE).
Nº publicación: US2025387564A1 25/12/2025
Applicant:
UNIV OF GALWAY [IE]
University of Galway
Absstract of: US2025387564A1
An extended duration infusion set/system suitable for transcutaneous delivery of a treatment fluid to a subject is described. The infusion set reduces and delays fibrotic capsule formation on and around an infusion cannula, and increases the effective lifetime of an infusion set significantly. The infusion set comprises a deflectable therapy reservoir to “actively” diffuse insulin and negate the effects of the foreign body response (FBR).
BOPI
Electronic site
